Endothelin-1 traps potently reduce pathologic markers back to basal levels in an in vitro model of diabetes

Background Diabetes mellitus is a group of metabolic disorders in which there are high blood glucose levels over a prolonged period. Diabetes is one of many diseases associated with pathologically elevated levels of endothelin (ET)-1. We have recently proposed the development of ET-traps, which are an antibody – based fusion protein that potently bind and sequester pathologically elevated levels of endothelin-1.